STARDUST · Project

Tiny Wireless Brain Implant Delivers Light and Drugs to Treat Parkinson's Disease

healthPrototypeTRL 3Thin data (2/5)

Imagine a grain of sand that can be placed inside the brain, powered wirelessly by ultrasound from outside the skull. That's what STARDUST built — a micro-device just 200 micrometers across that can stimulate brain cells with light, record their activity, and even release tiny doses of medication right where they're needed. They tested it in living mice to prove it works for Parkinson's Disease circuits. The same platform could one day target cancer tumors or other brain disorders.

By the numbers

200x200x200 µm³

Device size — smaller than a grain of sand

1-20 mW/mm²

Optical output power for brain cell stimulation

Light wavelengths for neuron activation and drug delivery triggering

Consortium partners across 8 countries

Industry partners including SMEs in the consortium

Total project deliverables produced

The business problem

What needed solving

Treating Parkinson's Disease today relies on systemic drugs with widespread side effects or bulky wired brain stimulation devices that limit patient mobility. There is no commercially available technology that can simultaneously stimulate specific brain circuits with light, monitor their electrical activity, and deliver drugs locally — all from a wireless micro-device. STARDUST addresses this gap with a platform small enough to be minimally invasive and versatile enough to combine all three functions.

The solution

What was built

The project built and validated a wireless, ultrasonically-powered micro-implant (200x200x200 µm³) that performs optogenetics, electrophysiology, and local drug delivery. The key demo deliverable confirmed in vivo functionality: the basic device was tested in mouse motor cortex with behavioral readout on locomotor activity in transgenic mice, proving the core concept works in living brain tissue.

Audience

Who needs this

Neuromodulation device manufacturers (Medtronic, Boston Scientific, Abbott Neuromodulation)Pharma companies with CNS pipelines needing targeted drug delivery solutionsMEMS and bioelectronics fabrication companies seeking medical device applicationsNeuroscience research tool companies (e.g., NeuroNexus, Neurophotometrics)Venture capital firms investing in neurotechnology and brain-computer interfaces

Business applications

Who can put this to work

Medical devices and neurotechnology

enterprise

Target: Neuromodulation device manufacturers

If you are a medical device company developing treatments for Parkinson's Disease — this project built and validated a 200x200x200 µm³ wireless implant that combines optogenetics, electrophysiology, and local drug delivery in one device. The in vivo proof of concept in mouse motor cortex demonstrates a platform that could replace bulky wired brain stimulation hardware with a minimally invasive alternative. Licensing or co-developing this technology could give you a next-generation product pipeline for neurological disorders.

Pharmaceutical and drug delivery

enterprise

Target: Pharma companies developing CNS-targeted therapies

If you are a pharmaceutical company struggling with getting drugs past the blood-brain barrier — STARDUST demonstrated ultra-localized drug delivery triggered by light, at the exact brain location where it is needed. This approach could dramatically improve drug efficacy while reducing systemic side effects. The platform was validated in freely moving animals, showing real-world applicability beyond lab-bench setups.

Semiconductor and MEMS manufacturing

mid-size

Target: Companies producing miniaturized bioelectronic components

If you are a MEMS or semiconductor company looking for high-value applications of your micro-fabrication capabilities — this project needs manufacturing partners who can produce ultrasonically-powered chips, micro-LEDs, and MEMS drug delivery systems at the 200 µm scale. The consortium includes 3 industry partners and 3 SMEs already, but volume production for clinical trials will require specialized fab capacity.

Frequently asked

Quick answers

What would it cost to license or co-develop this technology?

The project does not publish licensing terms. Since STARDUST was funded under FET Open (high-risk, early-stage research), the technology is at proof-of-concept stage. Costs would depend on negotiations with Aarhus University and consortium partners. Expect significant further R&D investment before any commercial product.

Can this be manufactured at industrial scale?

The device integrates MEMS, micro-LEDs, and nanoelectronics at 200x200x200 µm³ scale. While proof of concept was demonstrated, scaling to clinical-grade manufacturing with regulatory approval would require substantial engineering and validation work. The consortium includes 3 industry partners who contributed manufacturing expertise.

Who owns the intellectual property?

IP is shared among the 10-partner consortium across 8 countries, coordinated by Aarhus University in Denmark. FET Open grants typically allow partners to retain IP they generate. Specific licensing arrangements would need to be negotiated with the relevant consortium members.

What regulatory path would this need?

As an implantable brain device combining optogenetics and drug delivery, this would face stringent regulatory requirements — likely Class III medical device classification in the EU (MDR) and FDA PMA in the US. The current validation is in transgenic mice, meaning human clinical trials are still years away.

How far along is this technology really?

The project delivered in vivo validation of the basic device in mouse motor cortex with behavioral readout on locomotor activity. This is a solid proof of concept but still pre-clinical. The project explicitly describes itself as establishing a foundation for future applications beyond 2025.

Could this platform work for conditions beyond Parkinson's?

Yes — the project objective explicitly mentions photodynamic therapy for cancer treatment and other neurological and non-neurological disorders as future applications. The core platform of wireless ultrasonic power, light delivery, and localized drug release is disease-agnostic.

What technical support is available from the consortium?

The 10-partner consortium spans universities, research institutes, and industry across 8 countries including Denmark, Germany, France, and Sweden. Based on available project data, 15 deliverables were produced covering device design, fabrication, and in vivo testing. The project website at project-stardust.eu may provide additional technical documentation.

Consortium

Who built it

The STARDUST consortium brings together 10 partners from 8 countries — a genuinely international team with 4 universities, 3 research institutes, and 3 industry players (all SMEs). The 30% industry ratio is respectable for such early-stage research, signaling commercial awareness even at the proof-of-concept phase. Aarhus University in Denmark leads the coordination. The geographic spread across Belgium, Brazil, Germany, Denmark, Finland, France, Ireland, and Sweden suggests access to diverse manufacturing and regulatory expertise, though the inclusion of a Brazilian partner is unusual for Horizon 2020 and may indicate specialized optogenetics or neuroscience capability. For a business partner, the SME involvement means there are already commercially-minded entities in the consortium who understand productization challenges.

AARHUS UNIVERSITETCoordinator · DK
BIOMODICS APSparticipant · DK
SPINVERSE ABthirdparty · SE
SPINVERSE OYparticipant · FI
VIB VZWparticipant · BE
HUMBOLDT-UNIVERSITAET ZU BERLINparticipant · DE
Universidade Federal do Paráparticipant · BR
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRSparticipant · FR
UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORKparticipant · IE

How to reach the team

Aarhus University, Denmark — reach out to the Department of Engineering or Biomedical Engineering for the project lead.

Order a report on this consortium See AARHUS UNIVERSITET profile →

Next steps

Talk to the team behind this work.

Want an introduction to the STARDUST team? SciTransfer can connect you with the right consortium partner for licensing, co-development, or technical consultation.

Order a report on this topic More in Health & Biomedical